Biochem/physiol Actions
Cell permeable: no
Reversible: no
Target IC50: 5 µM as TNF-α antagonist
Product does not compete with ATP.
General description
An exocyclic peptidomimetic that acts as a TNF-α antagonist (IC50 = 5 µM) in the binding assay. Blocks TNF-α-mediated apoptosis in mouse L929 cells. The designation WP9QY arises from the binding to the site observed in the TNF-β/TNF-receptor (I) complex as template, and the introduction of amino acids Glu and Tyr.
An exocyclic peptidomimetic that acts as a TNF-α antagonist (IC50 = 5 µM) in binding assay. Blocks TNF-α-mediated apoptosis in mouse L929 cells. Exhibits about twofold higher activity than other known WP5 binding site derived mimetics. Designation WP9QY arises from the binding to the WP9 binding site of the TNF-β/TNF-receptor(I) complex as template, and the introduction of amino acids, Gln and Tyr.
Legal Information
Sold under license of U.S. Patent 6,265,535.
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Takasaki, W., et al. 1997. Nat. Biotechnol. 15, 1266.
Packaging
1 mg in Plastic ampoule
Sequence
H-Tyr-Cys-Trp-Ser-Gln-Tyr-Leu-Cys-Tyr-OH (disulfide bond: 2 → 8)
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: